Tumor biopsies and advanced multiplex immunofluorescence enable quantification of immune cell subsets including their precise placement within the tumor microenvironment—yet getting samples can put patients at risk. Liquid biopsies are less invasive and enable monitoring of circulating biomarkers. In this presentation, we will show an innovative strategy utilizing liquid biopsies to assess biomarkers in both circulating tumor cells (CTCs) and peripheral immune cells from the same patient sample.
Our proprietary ApoStream® technology was developed as part of a National Cancer Institute (NCI) initiative to support the development of a rare cell enrichment device for the isolation of circulating tumor cells (CTCs) from whole blood. ApoStream® is the only CTC technology co-developed and co-funded by the NCI and is currently being used by laboratories at the NCI to enable biomarker detection using liquid biopsies for oncology therapeutic development.
Precision’s specialty lab scientists take a collaborative and consultative approach to projects and can provide recommendations on biomarker assay strategies and implementation. Services can be provided individually or as part of a comprehensive therapeutic development package including biomarker assays and clinical trials. To learn more about our services contact us today.
NEW VIDEO: Biomarker Strategies in Cancer Immunotherapy